Evolus EOLS Product revenue, net — Total net revenues

Other product segments

Similar metrics at other companies

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

Questions, answered.

What is Evolus's product revenue, net — total net revenues?

Evolus (EOLS) reported product revenue, net — total net revenues of $72.75M in Q1 2026.

How has Evolus's product revenue, net — total net revenues changed year-over-year?

Evolus's product revenue, net — total net revenues increased by 6.9% year-over-year, from $68.07M to $72.75M.

What is the long-term trend for Evolus's product revenue, net — total net revenues?

Over 4 years (2021 to 2025), Evolus's product revenue, net — total net revenues has grown at a 31.4% compound annual growth rate (CAGR), from $98.97M to $294.96M.

What does product revenue, net — total net revenues mean?

This metric represents the total net revenue generated from the sale of the company's primary aesthetic pharmaceutical products after accounting for returns, allowances, and discounts. It serves as a key indicator of market adoption and commercial performance within the self-pay aesthetic medical market. Growth in this segment reflects the company's ability to expand its customer base and increase product penetration in the competitive neurotoxin landscape.